The purpose of the series, Advances in Antiviral Drug Design, is to regularly provide an account on the chemistry of the new antiviral agents (whether licensed or en route of licensing), and to discuss their structure-activity relationship, width of activity spectrum, and mechanism of action.
In Volume 1, G.D. Diana and T.J. Nitz begin with the chemistry of the capsid uncoating inhibitors that are active against picornaviruses. Then R.K. Robins and G.R. Revankar discuss ß-D-ribofuranosyl nucleosides (like ribavirin) that are active against a broad spectrum of RNA viruses. The acyclic nucleoside analogues (like acyclovir and ganciclovir) are described by N.G. Johansson, and the acyclic nucleoside phosphonates (like HPMPC and PMEA) are addressed by A. Holy. Finally, P. Herdewijn, J. Balzarini, and E. De Clercq review the anti-HIV potential of the class of the 2',3'-dideoxynucleoside analogues to which AZT, DDI, and DDC belong.
In Volume 1, G.D. Diana and T.J. Nitz begin with the chemistry of the capsid uncoating inhibitors that are active against picornaviruses. Then R.K. Robins and G.R. Revankar discuss ß-D-ribofuranosyl nucleosides (like ribavirin) that are active against a broad spectrum of RNA viruses. The acyclic nucleoside analogues (like acyclovir and ganciclovir) are described by N.G. Johansson, and the acyclic nucleoside phosphonates (like HPMPC and PMEA) are addressed by A. Holy. Finally, P. Herdewijn, J. Balzarini, and E. De Clercq review the anti-HIV potential of the class of the 2',3'-dideoxynucleoside analogues to which AZT, DDI, and DDC belong.
